CYP-001 is Cynata's lead Cymerus mesenchymal stem cell (MSC) product. Cynata plans to conduct the Phase 1 clinical trial, which is entitled "An Open-Label Phase 1 Study to Investigate
Redx scientists have demonstrated that the Porcupine inhibitor could have a crucial role in improving the immune system response of some cancer patients when used in combination with
In anticipation of substantial growth across Alnylam over the next five years, the office opens with a core Clinical Development, Regulatory Affairs, and Commercial team and space for
The offering was upsized by $25 million over the offering amount anticipated to be sold as previously announced. This is in addition to $50 million raised separately through
Under the terms of the collaboration, Dr. Reddy’s will commercialise XGEVA (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India. In 2015, Dr. Reddy’s announced an initial strategic collaboration with Amgen to
Under the license, TeneoBio will be able to use the OmniFlic technology from the OmniAb platform to discover fully human bispecific antibodies to be developed for the treatment of various
The financing round included new investor Foresite Capital Management and participation from all existing investors, including Remeditex LLC, The Column Group, Tichenor Ventures LLC, Topspin Fund LP, and
Paul Foster, M.D., chief medical officer at Xencor, said: "A previously completed Phase 1a study of intravenous administration of XmAb7195 has shown potent suppression of IgE, in particular demonstrating
YOSPRALA is indicated for patients who require aspirin for secondary prevention of cardiovascular (CV) and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers.
The study achieved its primary efficacy endpoint demonstrating statistical superiority over each of its components, including Aerie product candidate Rhopressa (netarsudil ophthalmic solution) 0.02%, and market leading prostaglandin analogue
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.